Filing Details

Accession Number:
0001104659-24-008327
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-30 17:03:13
Reporting Period:
2024-01-26
Accepted Time:
2024-01-30 17:03:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1454789 Astria Therapeutics Inc. ATXS Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1859284 Christopher Morabito C/O Astria Therapeutics, Inc.
75 State Street, Suite 1400
Boston MA 02109
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-26 800 $3.87 800 No 4 M Direct
Common Stock Disposition 2024-01-26 800 $11.02 0 No 4 S Direct
Common Stock Acquisiton 2024-01-29 9,200 $3.87 9,200 No 4 M Direct
Common Stock Disposition 2024-01-29 9,200 $11.15 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-01-26 800 $0.00 800 $3.87
Common Stock Stock Option (Right to Buy) Disposition 2024-01-29 9,200 $0.00 9,200 $3.87
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
99,200 2032-07-31 No 4 M Direct
90,000 2032-07-31 No 4 M Direct
Footnotes
  1. This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.02, inclusive. The reporting person undertakes to provide to Astria Therapeutics, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  4. The option was granted on August 1, 2022, pursuant to the Issuer's 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the option grant. This option is subject to vesting over a four year period, with 25% of shares vested on the first anniversary of July 14, 2022, the reporting person's employment start date, and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.